Spiradoline

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Spiradoline
Accession Number
DB12704
Type
Small Molecule
Groups
Investigational
Description

Spiradoline has been investigated for the basic science of Bipolar Depression.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
N18ZH0M4NP
CAS number
87151-85-7
Weight
Average: 425.39
Monoisotopic: 424.1684336
Chemical Formula
C22H30Cl2N2O2
InChI Key
NYKCGQQJNVPOLU-ONTIZHBOSA-N
InChI
InChI=1S/C22H30Cl2N2O2/c1-25(21(27)14-16-5-6-17(23)18(24)13-16)19-7-9-22(8-4-12-28-22)15-20(19)26-10-2-3-11-26/h5-6,13,19-20H,2-4,7-12,14-15H2,1H3/t19-,20-,22-/m0/s1
IUPAC Name
2-(3,4-dichlorophenyl)-N-methyl-N-[(5R,7S,8S)-7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]decan-8-yl]acetamide
SMILES
[H][[email protected]@]1(CC[[email protected]@]2(CCCO2)C[[email protected]]1([H])N1CCCC1)N(C)C(=O)CC1=CC(Cl)=C(Cl)C=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Spiradoline.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Spiradoline.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Spiradoline.Illicit
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Spiradoline.Experimental, Illicit, Withdrawn
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Spiradoline.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Spiradoline.Approved, Illicit, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Spiradoline.Illicit, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Spiradoline.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Spiradoline.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Spiradoline.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Spiradoline.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Spiradoline.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Spiradoline.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Spiradoline.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Spiradoline.Approved, Illicit
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Spiradoline.Investigational
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Spiradoline.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Spiradoline.Illicit, Vet Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Spiradoline.Approved, Illicit, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Spiradoline.Approved, Illicit
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Spiradoline.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Spiradoline.Approved, Illicit
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Spiradoline.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Spiradoline.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Spiradoline.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Spiradoline.Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Spiradoline.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Spiradoline.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Spiradoline.Approved, Illicit
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Spiradoline.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Spiradoline.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Spiradoline.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Spiradoline.Approved, Illicit
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Spiradoline.Approved, Illicit
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Spiradoline.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Spiradoline.Approved, Investigational, Vet Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Spiradoline.Approved, Vet Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Spiradoline.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Spiradoline.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Spiradoline.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Spiradoline.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Spiradoline.Approved
Sodium phosphateSpiradoline may increase the nephrotoxic activities of Sodium phosphate.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Spiradoline.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Spiradoline.Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Spiradoline.Experimental
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Spiradoline.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
ChemSpider
50257
BindingDB
83436
ChEMBL
CHEMBL70586
ATC Codes
Not Available
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceDepression, Bipolar1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0147 mg/mLALOGPS
logP4.27ALOGPS
logP3.81ChemAxon
logS-4.5ALOGPS
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area32.78 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity114.04 m3·mol-1ChemAxon
Polarizability45 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylacetamides. These are amide derivatives of phenylacetic acids.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylacetamides
Direct Parent
Phenylacetamides
Alternative Parents
Dichlorobenzenes / N-alkylpyrrolidines / Aryl chlorides / Tertiary carboxylic acid amides / Oxolanes / Trialkylamines / Amino acids and derivatives / Oxacyclic compounds / Dialkyl ethers / Azacyclic compounds
show 4 more
Substituents
Phenylacetamide / 1,2-dichlorobenzene / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / N-alkylpyrrolidine / Tertiary carboxylic acid amide / Pyrrolidine / Oxolane
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 17:41 / Updated on September 01, 2017 12:24